Venue: Hotel Bayerischer Hof

Location: Munich, Germany

Event Date/Time: May 23, 2001 End Date/Time: May 24, 2001
Paper Submission Date: Apr 13, 2001
Report as Spam


Pharmacogenomics is widely touted as the chief lady in waiting to the Human Genome Project. Clinical results are gathering to provide evidence that this is not just hype. Recently a biotech company discovered four genes whose haplotypes, when combined in a multigene model, resulted in a genetic profile of each drug's effectiveness. The ability to predict a drug response will have a substantial impact on drug marketing practices and may lead to a shakeup of the industry on a general scale. This leads us to question whether "Mass Customization" is a dream come true or a bitter pill for pharmaceutical companies to swallow. As a sidebar to this exciting moment, we should also note that North America came out ahead in the race to map our genes-but is Europe poised to take the lead with more direct biological implementation of disease etiology and protein function?